Evidence map›Paper›PMID 42281286›Full record

Trial reportAmerican journal of respiratory and critical care medicine2026

Defining disease stability in chronic obstructive pulmonary disease: evidence from phase 3 clinical trials.

Dave Singh, Rianne Stacey, David M G Halpin, Surya P Bhatt, Jodie Crawford, Thomas Drury, Valentina Di Boscio, Stefanie Kolterer, MeiLan K Han

Abstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American journal of respiratory and critical care medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Dave SinghCentre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, University of Manchester, Manchester University NHS Foundation Trust, Manchester, United Kingdom.ORCID 0000-0001-8918-7075
Rianne StaceyGlobal Medical Affairs, General Medicines, GSK, London, United Kingdom.ORCID 0000-0002-6516-3172
David M G HalpinThe College of Medicine & Health, University of Exeter Medical School, University of Exeter, Exeter, United Kingdom.ORCID 0000-0003-2009-4406
Surya P BhattDivision of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.ORCID 0000-0002-8418-4497
Jodie CrawfordDevelopment Biostatistics, GSK, London, United Kingdom.ORCID 0000-0003-0150-0333
Thomas DruryDevelopment Biostatistics, GSK, London, United Kingdom.ORCID 0000-0003-1443-5999
Valentina Di BoscioGlobal Medical Affairs, General Medicines, GSK, London, United Kingdom.
Stefanie KoltererSpecialty Medicines, GSK, London, United Kingdom.
MeiLan K HanDivision of Pulmonary and Critical Care, University of Michigan, Ann Arbor, MI, United States.ORCID 0000-0002-9095-4419

Funding

GSK 208657GSK CT116853GSK CT116855GSK MEA117106GSK MEA117113
6 · The paper itself

Abstract

rationaleDisease stability in chronic obstructive pulmonary disease (COPD) is a low disease activity state proposed as a treatment target.

objectivesCharacterize COPD stability as a composite endpoint.

methodsPost hoc analyses were carried out on IMPACT and FULFIL (fluticasone furoate/umeclidinium/vilanterol [FF/UMEC/VI] vs dual therapies) and MATINEE/METREX/METREO (mepolizumab added onto triple therapy). Stability was defined as "no moderate/severe exacerbations and no worsening from baseline in COPD Assessment Test (CAT) and FEV1." We assessed whether achieving stability at week 28 was prognostic of subsequent outcomes (time to first on-treatment moderate/severe exacerbation and time to all-cause mortality [ACM]) after week 28 (IMPACT). Bayesian joint modeling evaluated the probability of achieving stability (IMPACT). MEASUREMENTS AND MAIN

resultsStability was achieved with FF/UMEC/VI by 22% of patients in IMPACT (week 52) and by 46% of patients in FULFIL (week 24); stability was achieved with mepolizumab + triple therapy by 18% of patients in MATINEE/METREX/METREO (week 52). Patients were more likely to achieve stability with triple vs dual therapy and with mepolizumab vs placebo. Many individuals achieving stability had clinically meaningful improvements in CAT and FEV1. Patients achieving stability at week 28 (vs patients who were not stable) had a 45.7% reduction in the risk of moderate/severe exacerbations and a 51.7% reduction in the risk of ACM after week 28. Bayesian joint modeling demonstrated a mean (SD) posterior probability of stability: 25.60% (0.66) at week 52 (FF/UMEC/VI).

conclusionsOur data provide further evidence for disease stability as an achievable COPD treatment target that predicts long-term clinical benefits in exacerbations and mortality.

Indexed as

AndrostadienesBenzyl AlcoholsBronchodilator AgentsChlorobenzenesPulmonary Disease, Chronic ObstructiveQuinuclidinesAgedDisease ProgressionDrug CombinationsDrug Therapy, CombinationFemaleForced Expiratory VolumeHumansMaleMiddle AgedTreatment OutcomeAndrostadienesBenzyl AlcoholsBronchodilator AgentsChlorobenzenesDrug Combinationsfluticasone furoateGSK573719Quinuclidinesvilanterolchronic obstructive pulmonary diseasedisease stabilitypatient-reported outcome measureprompt optimizationtreatment outcome

Identifiers

PMID42281286
PMCPMC13519310

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.